Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Mirati Therapeut Set to Possibly Rebound After Yesterday's Selloff of 2.00%

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $96.37 to a high of $99.60. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of...

MRTX : 93.41 (-4.61%)
Shares of MRTX Up 18.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on March 25th, 2020 at $82.01. In approximately 2 months, Mirati Therapeut has returned 18.62% as of today's recent price of $97.28.

MRTX : 93.41 (-4.61%)
After Yesterday's Decline of 1.10%, Mirati Therapeut Offers Investors Better Value

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $97.79 to a high of $101.17. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of...

MRTX : 93.41 (-4.61%)
Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that , M.D. has been named Chief Medical Officer effective . , M.D., will step...

MRTX : 93.41 (-4.61%)
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's pipeline of novel therapeutics...

MRTX : 93.41 (-4.61%)
SmarTrend Watching for Potential Pullback in Shares of Mirati Therapeut After 7.96% Gain

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $106.13 to a high of $114.48. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high...

MRTX : 93.41 (-4.61%)
Mirati (MRTX) Reports Q1 Loss, Lags Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

MRTX : 93.41 (-4.61%)
Mirati: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Thursday reported a loss of $86.7 million in its first quarter.

MRTX : 93.41 (-4.61%)
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the first quarter ended .

MRTX : 93.41 (-4.61%)
Shares of MRTX Up 9.9% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on March 25th, 2020 at $82.01. In approximately 1 month, Mirati Therapeut has returned 9.86% as of today's recent price of $90.09.

MRTX : 93.41 (-4.61%)
Analysts Estimate Mirati (MRTX) to Report a Decline in Earnings: What to Look Out for

Mirati (MRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MRTX : 93.41 (-4.61%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Mirati Therapeutics, Inc.-MRTX

NEW YORK, NY / ACCESSWIRE / April 22, 2020 / Levi & Korsinsky announces it has commenced an investigation of Mirati Therapeutics, Inc. (NASDAQ:MRTX) concerning possible breaches of fiduciary duty. To obtain...

MRTX : 93.41 (-4.61%)
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Mirati Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...

MRTX : 93.41 (-4.61%)
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Mirati Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims

Fields Kupka & Shukurov LLP is investigating potential breach of fiduciary duty claims involving the board of directors of Mirati Therapeutics, Inc. (NASDAQ: MRTX).

MRTX : 93.41 (-4.61%)
6.5% Return Seen to Date on SmarTrend Mirati Therapeut Call (MRTX)

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on March 25th, 2020 at $82.01. In approximately 3 weeks, Mirati Therapeut has returned 6.54% as of today's recent price of $87.37.

MRTX : 93.41 (-4.61%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (NTRA , AKBA , NVAX , CYTK , MRTX)

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

AKBA : 12.18 (+2.48%)
NTRA : 41.20 (-4.96%)
NVAX : 44.66 (+0.93%)
MRTX : 93.41 (-4.61%)
Mirati Therapeut Down 15.4% Since SmarTrend Downtrend Call (MRTX)

SmarTrend identified a Downtrend for Mirati Therapeut (NASDAQ:MRTX) on February 27th, 2020 at $86.08. In approximately 3 weeks, Mirati Therapeut has returned 15.35% as of today's recent price of $72.86....

MRTX : 93.41 (-4.61%)
Mirati: 4Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Tuesday reported a loss of $72.4 million in its fourth quarter.

MRTX : 93.41 (-4.61%)
Mirati Therapeutics Reports Year-End 2019 Financial Results And Recent Corporate Updates

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year-ended December 31, 2019.

MRTX : 93.41 (-4.61%)
SmarTrend Watching for Potential Pullback in Shares of Mirati Therapeut After 2.14% Gain

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $97.36 to a high of $99.34. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high...

MRTX : 93.41 (-4.61%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -2.76 , SEDG -8.19 , THC -0.44 , TER +0.87 , LITE -1.62
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar